Evotec Seals Deal With Pfizer In Tissue Fibrosis
This article was originally published in Scrip
Following swiftly on from its immuno-oncology therapy deal with Sanofi, Evotec has agreed on a four-year research collaboration with Pfizer in tissue fibrosis.
You may also be interested in...
Werner Lanthaler talks to Jo Shorthouse about partnering with big pharma on drug discovery, remaining authentic, and creating the 'half pregnant' company that Evotec is today.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.